Analytical Data
-
基因名
KDM6B
- Application
-
别名
(JmjC domain-containing protein 3)(Jumonji domain-containing protein 3)(Lysine demethylase 6B)([histone H3]-trimethyl-L-lysine(27) demethylase 6B)
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O15054
-
表达区间
1176-1505aa
-
分子量
41.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KDM6B, also known as Jumonji Domain Containing 6B, is a histone demethylase that plays a crucial role in the regulation of gene expression through the removal of methyl groups from lysine 27 on histone H3 (H3K27me3). This modification is a key epigenetic marker associated with gene silencing and is involved in various biological processes including stem cell differentiation, development, and the maintenance of pluripotency. Dysregulation of KDM6B has been implicated in several diseases, particularly cancer, where altered gene expression patterns can lead to tumorigenesis and metastasis. Therefore, the study of KDM6B and its recombinant protein holds significant promise for understanding the mechanistic pathways of epigenetic regulation. Researchers have focused on developing recombinant KDM6B proteins to investigate their enzymatic activity, molecular interactions, and potential as therapeutic targets. Furthermore, understanding how KDM6B functions in the context of histone modifications can provide insights into the epigenetic landscape of various diseases, paving the way for new strategies in epigenetic therapy. As a result, KDM6B is a focal point of research aimed at elucidating its role in epigenetics and its potential as a biomarker or therapeutic target in oncology and regenerative medicine.
